Ikena Oncology Inc has entered into a merger agreement with Inmagene Biopharmaceuticals, where Inmagene will merge into Ikena's subsidiary, resulting in Inmagene becoming a wholly owned subsidiary of Ikena, with ownership stakes of approximately 55.6% for Inmagene shareholders and 44.4% for Ikena shareholders post-merger, along with a PIPE financing of $75 million.